John N. Allan
- Genetics top 1%
- Pathology and Forensic Medicine top 2%
- Oncology top 10%
- Immunology top 10%
- Hematology top 5%
- Co-authors
- Richard R. FurmanThomas J. KippsMónica L. GuzmánWilliam G. WierdaJames P. DeanPaolo GhiaTanya SiddiqiConstantine S. Tam
- Topics
- Chronic Lymphocytic Leukemia Research (76 papers)Lymphoma Diagnosis and Treatment (41 papers)Chronic Myeloid Leukemia Treatments (14 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- United StatesItalyAustralia
In The Last Decade
John N. Allan
82 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 53
- Genetics 803
- Pathology and Forensic Medicine 708
- Oncology 333
- Immunology 319
- Hematology 286
Countries citing papers authored by John N. Allan
This map shows the geographic impact of John N. Allan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John N. Allan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John N. Allan more than expected).
Fields of papers citing papers by John N. Allan
This network shows the impact of papers produced by John N. Allan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John N. Allan. The network helps show where John N. Allan may publish in the future.
Co-authorship network of co-authors of John N. Allan
This figure shows the co-authorship network connecting the top 25 collaborators of John N. Allan. A scholar is included among the top collaborators of John N. Allan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John N. Allan. John N. Allan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 14 | |
| 4 | 2 | |
| 5 | 1 | |
| 6 | 8 | |
| 7 | 0 | |
| 8 | 0 | |
| 9 | 0 | |
| 10 | 1 | |
| 11 | 0 | |
| 12 | 20 | |
| 13 | 2 | |
| 14 | 6 | |
| 15 | Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohortbreakdown → | 124 |
| 16 | 76 | |
| 17 | 6 | |
| 18 | 31 | |
| 19 | 33 | |
| 20 | 2 |
About John N. Allan
John N. Allan is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology, having authored 97 papers that have together received 1.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (76 papers), Lymphoma Diagnosis and Treatment (41 papers) and Chronic Myeloid Leukemia Treatments (14 papers). The work is most often cited by research in Genetics (803 citations), Pathology and Forensic Medicine (708 citations) and Hematology (286 citations). John N. Allan has collaborated with scholars based in United States, Italy and Australia. Frequent co-authors include Richard R. Furman, Thomas J. Kipps, Mónica L. Guzmán, William G. Wierda, James P. Dean, Paolo Ghia, Tanya Siddiqi, Constantine S. Tam, Cathy Zhou and Silvia Deaglio. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.